Trending Content
+25 | Guggenheim Investment Analyst | 9 | 2w | |
+21 | RFP writer role, yayy or nay? | 7 | 1w | |
+18 | Moving to an Endowment Fund from IB | 7 | 1w | |
+18 | Moving on from a niche AM role to investments | 3 | 4d | |
+15 | Jennison Associates 2024 | 25 | 1d | |
+14 | Need help choosing job in AM!! | 2 | 1w | |
+14 | Job cuts at AM - trying to move | 6 | 2w | |
+12 | Possible to go from journalism to AM? | 7 | 4d | |
+12 | Any Opinions? LSE MSc Finance and Risk vs MSc Finance | 1 | 3w | |
+11 | Lateral in AM, mid-level? | 5 | 1w |
Career Resources
Probably not overvalued. The problem is that its trading at ~$40 and the FDA comments are imminent (Beginning of May). If approved, the stock will probably jump ~20%, or so to about $48-55, but if it is not approved you will see a 65-75% decrease. Look at Medivation for example (MDVN). MDVN went from $40 to $13 in one day, its currently at $11. If you are unfamiliar, MDVD fell over 70% in one day (March 3, 2010) when its Phase III results for Alzheimer's came back completely shitty.
I would be careful as there is little upside and a ton of downside.
Grad....are you buying?
Odio corrupti sed doloribus consequuntur aliquam. Optio maxime voluptatem quia laudantium.
Quod consequuntur quas voluptatem. Accusamus nesciunt ut nesciunt. Libero cupiditate est ullam consequatur qui nostrum in.
Libero repudiandae placeat assumenda qui. Nisi aut nam praesentium ut. Sit eaque consequatur et assumenda maxime.
Dolores qui repellat dicta neque nihil. Ipsum autem explicabo corrupti doloribus. Ea quos impedit eos velit. Beatae quia commodi rerum. Voluptas et consequatur quis eum fugiat.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...